orantinib has been researched along with Cancer of Prostate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Li, H; Liu, C; Qian, B; Yao, Y; Zhang, J | 1 |
| Abdollahi, A; Debus, J; Hahnfeldt, P; Han, X; Hlatky, L; Howlett, AR; Huber, PE; Krempien, R; Lipson, KE; Trinh, T; Weber, KJ | 1 |
| Devlin, J; Gorelik, E; Huang, X; Krasinskas, A; Lokshin, A; Raskovalova, T; Watkins, S; Wolf, SF | 1 |
3 other study(ies) available for orantinib and Cancer of Prostate
| Article | Year |
|---|---|
SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
Topics: Angiogenesis Inhibitors; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Membrane Proteins; Neoplasm Invasiveness; Oxindoles; Propionates; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; RNA-Binding Proteins; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Topics: Angiogenesis Inhibitors; Cell Division; Cells, Cultured; Dose-Response Relationship, Radiation; Endothelial Growth Factors; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Kinetics; Lymphokines; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Oxindoles; Particle Accelerators; Propionates; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; X-Rays | 2003 |
Combined antiangiogenic and immune therapy of prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Cell Line, Tumor; Immunoglobulin G; Immunotherapy; Indoles; Male; Mice; Oxindoles; Propionates; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Recombinant Fusion Proteins; T-Lymphocytes | 2005 |